Seth Potash, MD
Ophthalmology · Harrison, NYNPI 1043252273
Payments from drug & device makers
Across 685 payments — averaging $215.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$44K
- Glaukos Corporation$42K
- Aerie Pharmaceuticals, Inc.$29K
- Alcon$21K
- NEW World Medical,inc.$3K
- Johnson & Johnson Surgical Vision, Inc.$2K
- plus $7K from 27 others
What the payments were for
- Consulting fees$41,52828%
- Speaking & faculty fees$75,78751%
- Travel & lodging$7,4505%
- Food & beverage$22,81615%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 227 | $44,085 |
| Glaukos Corporation | 39 | $41,629 |
| Aerie Pharmaceuticals, Inc. | 52 | $29,354 |
| Alcon | 113 | $20,614 |
| NEW World Medical,inc. | 6 | $3,342 |
| Johnson & Johnson Surgical Vision, Inc. | 14 | $1,833 |
| Sun Pharmaceutical Industries Inc. | 43 | $1,239 |
| Kala Pharmaceuticals, Inc. | 38 | $1,107 |
| Sight Sciences, Inc. | 19 | $955 |
| Bausch & Lomb Americas Inc. | 21 | $934 |
| Novartis | 29 | $462 |
| Rxsight Inc | 4 | $340 |
| Amgen(2 entities) | 12 | $235 |
| Harrow Eye, LLC | 14 | $179 |
| Regeneron Healthcare Solutions, Inc. | 2 | $138 |
| Oyster Point Pharma, Inc. | 6 | $138 |
| Tarsus Pharmaceuticals, Inc. | 5 | $128 |
| Eyepoint US, Inc. | 6 | $118 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $103 |
| Alimera Sciences, Inc. | 5 | $101 |
| Ivantis, Inc | 1 | $81 |
| Astellas Pharma US Inc | 3 | $77 |
| Thea Pharma Inc. | 3 | $73 |
| Dompe US, Inc. | 3 | $61 |
| Rayner Intraocular Lenses Limited | 3 | $60 |
| Shire North American Group Inc | 2 | $46 |
| Biotissue Holdings Inc. | 2 | $32 |
| Ocular Therapeutix, Inc. | 2 | $29 |
| Eyevance Pharmaceuticals LLC | 1 | $25 |
| Boston Scientific | 1 | $21 |
| Merz Pharmaceuticals, LLC | 1 | $20 |
| Omeros Corporation | 1 | $13 |
| Spark Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$46,566
- Rhopressa$42,331
- LUMIGAN$33,625
- iDose$18,182
- COMBIGAN$15,516
- SIMBRINZA$5,514
- Ahmed Glaucoma Valve$2,865
- Kahook Dual Blade$2,865
- iStent Trabecular Micro-Bypass Stent System$2,725
- Streamline Surgical System$2,706
- Travoprost Intraocular Implant - iDose$2,313
- Radius XR$1,603
- Tecnis Symfony IOL$1,419
- Tecnis 1-piece IOL$1,087
- Tecnis Multifocal Family of 1-piece IOLS$1,087
- iDoseTR$765
- enVista MX60 IOL$704
- XEN$625
- XEN GLAUCOMA TREATMENT SYSTEM$621
- CEQUA$497
How this compares
$147,582 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 446 | $258,615 |
| RestasisCyclosporine | 150 | $186,356 |
| CombiganBrimonidine Tartrate/Timolol | 205 | $112,450 |
| RhopressaNetarsudil Mesylate | 135 | $86,027 |
| RocklatanNetarsudil Mesylat/Latanoprost | 103 | $67,809 |
| Alphagan PBrimonidine Tartrate | 137 | $58,771 |
| XiidraLifitegrast | 37 | $55,436 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 170 | $43,620 |
| VyzultaLatanoprostene Bunod | 58 | $35,090 |
| MieboPerfluorohexyloctane/Pf | 33 | $31,515 |
| XdemvyLotilaner | 17 | $31,281 |
| Prednisolone Acetate | 588 | $24,898 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 116 | $23,456 |
| Brinzolamide | 90 | $20,763 |
| IyuzehLatanoprost/Pf | 35 | $20,344 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $44,085 | $616,192938 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $29,354 | $153,835238 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $934 | $122,041128 claims |
| AlconSimbrinza, Azopt | $20,614 | $54,099191 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $128 | $31,28117 claims |
| Thea Pharma Inc.Iyuzeh | $73 | $20,34435 claims |
| NovartisTravatan Z | $462 | $15,08526 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,239 | $14,18011 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $103 | $3,12121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Harrison
- Omar ShakirHarrison$298K
- Douglas JabsNew York$24.3M
- David RubaltelliBrooklyn$8.9M
- Philip FerroneGreat Neck$5.8M
- Eric DonnenfeldGarden City$2.6M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
- Richard SpaideNew York$1.7M
- Paul HartmanRochester$1.6M
- Jason SlakterNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.